Full Text View
Tabular View
No Study Results Posted
Related Studies
Prostate Cancer Utilities and Cost-Effectiveness Analysis
This study is currently recruiting participants.
Verified by University of Chicago, March 2009
First Received: September 12, 2005   Last Updated: March 25, 2009   History of Changes
Sponsored by: University of Chicago
Information provided by: University of Chicago
ClinicalTrials.gov Identifier: NCT00203918
  Purpose

The purpose of this study is to help doctors and patients make better decisions about prostate cancer treatment. This research is being done because we do not know how patient preferences for health states related to prostate cancer affect the final treatment decision.


Condition Intervention
Prostate Cancer
Behavioral: Survey, interview

MedlinePlus related topics: Cancer Prostate Cancer
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Prostate Cancer Utilities and Cost-Effectiveness Analysis

Further study details as provided by University of Chicago:

Estimated Enrollment: 500
Study Start Date: January 2004
Intervention Details:
    Behavioral: Survey, interview
    A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
Detailed Description:

The goal of this project is to incorporate patients' preferences into a previously developed prostate cancer treatment decision-model and to understand the implications for doing so for cost-effectiveness analysis. To do this, it is first necessary to obtain patient utility scores (i.e., patient preference weights). To do this we will perform a survey of patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand the patients' individual evaluations of treatment-related health studies. We will also ask patients questions relating to their anxiety levels concerning the possible diagnosis of prostate cancer.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients visiting the urology clinic at the University of Chicago.

Criteria

Inclusion Criteria:

  • Patients undergoing prostate biopsy

Exclusion Criteria:

  • Women and children will be excluded, as prostate cancer occurs in men only
  • Diagnosis of dementia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00203918

Contacts
Contact: David Meltzer, M.D., Ph.D. 773-702-0836 dmeltzer@medicine.bsd.uchicago.edu

Locations
United States, Illinois
The University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: David Meltzer, M.D., Ph.D.     773-702-0836     dmeltzer@medicine.bsd.uchicago.edu    
Sub-Investigator: William Dale, M.D., Ph.D.            
Sub-Investigator: Gregory Zagaja, M.D.            
Sponsors and Collaborators
University of Chicago
Investigators
Principal Investigator: David Meltzer, M.D., Ph.D. University of Chicago
  More Information

No publications provided

Responsible Party: University of Chicago ( David Meltzer, MD, PhD )
Study ID Numbers: 12843B
Study First Received: September 12, 2005
Last Updated: March 25, 2009
ClinicalTrials.gov Identifier: NCT00203918     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by University of Chicago:
Prostate Cancer
Cost-Effectiveness Analysis
Utility Assessment

Study placed in the following topic categories:
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site
Prostatic Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Prostatic Neoplasms

ClinicalTrials.gov processed this record on May 07, 2009